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 EXTRA VIEW
How, and why, different proteins form amyloid fibrils is most often 
studied in vitro using a single purified 
protein sequence. However, many amy-
loid diseases involve co-aggregation of 
different protein species, including pro-
teins with/without post-translational 
modifications (e.g., different strains of 
PrP), proteins of different length (e.g., 
β
2
-microglobulin and ΔN6, Aβ40, 
and Aβ42), sequence variants (e.g., Aβ 
and Aβ
ARC
), and proteins from differ-
ent organisms (e.g., bovine PrP and 
human PrP). The consequences of co- 
aggregation of different proteins upon 
the structure, stability, species transmis-
sion and toxicity of the resulting amyloid 
aggregates is discussed here, including 
the role of co-aggregation in expanding 
the repertoire of oligomeric and fibrillar 
structures and how this can affect their 
biological and biophysical properties.
Introduction
It has been well documented that amy-
loid fibrils can be highly polymorphic, 
even when formed from proteins with 
the same amino acid sequence under the 
same incubation conditions.1 This poly-
morphism can be manifested through 
the formation of fibrils with different 
numbers and orientations of protofila-
ments, and also within the protofilament 
substructure, for example in the residues 
that contribute to the β-strand segments 
within the fibrils (reviewed in refs. 2–3). 
In a comprehensive study of an 11-residue 
transthyretin (TTR) peptide the struc-
ture and orientation of protofilaments 
from three different fibril polymorphs was 
described in atomic detail using cryo-elec-
tron microscopy (EM), scanning transmis-
sion EM and magic angle spinning (MAS) 
NMR, revealing different numbers of pro-
tofilaments within each polymorph.4 The 
different packing arrangements available 
for an amyloid fibril core has also been 
explored using X-ray crystallography of 
4–7-residue peptides from a variety of 
amyloidogenic proteins, the results reveal-
ing eight classes of polymorphs arranged 
as different steric zippers.5 The structures 
of the steric zippers differ in whether the 
β-strands are parallel or anti-parallel, 
whether the β-sheets pack face-to-face or 
back-to-back, and whether the sheets ori-
entate themselves up or down relative to 
each other6 (see Fig. 1A).
Oligomeric intermediates of amyloid 
formation can also show polymorphism. 
HypF-N is the 91-residue N-terminal 
domain of HypF, a carbamoyl transfer-
ase in Escherichia coli.7 In a recent study, 
oligomers of HypF-N formed under dif-
ferent solution conditions were shown to 
be similar, morphologically and tinctori-
ally, but differed in their ability to cause 
cell dysfunction.8 Further investigation 
using site-specific labeling with pyrene 
maleimide and binding of the dye 8- 
anilinonaphthalene-1-sulfonic acid (ANS) 
demonstrated that the oligomers that pos-
sess less structural order and expose more 
hydrophobic surface area are more toxic 
than oligomers with a more ordered core. 
The increased toxicity of one oligomer 
morphology over the other is thought to 
arise because the structural flexibility and 
hydrophobic exposure of the toxic oligo-
mers allows them to cross the hydrophobic 
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bilayer of the cell membrane, whereas the 
non-toxic oligomers can bind to, but not 
cross the membrane. In other examples 
the more structured oligomers were shown 
to be the most toxic.9 These examples, 
and many others,10-12 show the ability of 
a single polypeptide sequence to adopt an 
array of oligomeric structures with differ-
ing physical, chemical, biophysical and 
biological functions, even for species of 
similar molecular weight. This poses sig-
nificant challenges for the identification 
and structural characterization of each 
individual species in the amyloid cascade 
and in amyloid disease.
The above studies demonstrate 
that there is a large range of possible 
polymorphic structures available to an 
amyloidogenic protein or peptide both as 
oligomeric intermediates in fibril forma-
tion and in the final fibrillar form. The 
potential assortment of polymorphs can 
be greatly expanded when mixtures of pro-
teins can co-aggregate, either de novo or 
via cross-seeding. The resulting increased 
range of fibril structures expands the rep-
ertoire of aggregation propensities and 
amyloid stabilities. This can be useful, for 
example by providing enhanced opportu-
nity for tailoring the physical properties of 
amyloid fibrils for use as nanomaterials. 
However, it may also be detrimental, for 
example, by increasing the possibility for 
toxicity and disease.
Here we discuss the repertoire of amy-
loid polymorphs formed from different 
protein and peptide sequences, (the inter-
actions between amyloidogenic proteins 
and other important factors in amyloid 
fibril formation, such as chaperones, small 
molecules, metal ions, lipids, and glycolip-
ids, are not included).13 We identify three 
different scenarios that can affect the like-
lihood of two proteins cross-seeding and/
or co-polymerizing with each other. First, 
we discuss the requirements of sequence 
in determining co-aggregation propen-
sity and its outcomes. Second, we describe 
scenarios in which one protein increases 
the amyloidogenic propensity of another. 
Finally, we review the extent to which 
Figure 1. The potential repertoire of fibril polymorphs. (A) The eight classes of steric zipper available to a single polypeptide chain (re-drawn from Figure 
4 of Sawaya et al.).5 (B) A schematic of different possible fibril polymorphs that can arise from co-aggregation of more than one protein (depicted are 
ΔN6 [PDB code 2XKU] in pink and β
2
m [PDB code 2XKS] in purple).20
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both proteins need to have the ability to 
adopt a similar fibril structure in order 
to co-assemble. A select number of stud-
ies are discussed in detail in each section, 
and a more comprehensive list of protein-
protein interactions that expand the rep-
ertoire of fibril polymorphs is included in 
Table 1.
Condition 1: Co-Aggregation 
of Proteins/Peptides with 
Similar Primary Sequence
The intermolecular interactions that 
stabilize amyloid fibrils involve the pep-
tide backbone and thus the ability to form 
fibrils is considered to be a generic property 
of all polypeptide chains.14 However side-
chain interactions play a crucial role in the 
formation of amyloid fibrils and in deter-
mining the ability of one protein to seed 
polymerization of another. The impor-
tance of amino acid sequence similarity 
in cross-seeding (adding fibrillar seeds 
of one polypeptide sequence to mono-
mers of a second polypeptide sequence) 
was shown in a study of hen lysozyme 
(Row 1, Table 1).15 Fibrillar seeds cre-
ated from sequences that are 99.2% 
(I55T mutational variant of hen lysozyme) 
or 95% identical (turkey lysozyme) to that 
of the hen lysozyme monomer produced 
identical seeding behavior to homologous 
seeding. A seed with a sequence that is 
60% identical to the hen lysozyme mono-
mer (human lysozyme) showed faster fibril 
elongation than the rate of fibril forma-
tion of the unseeded monomer, but with a 
lag phase that is increased compared with 
self-seeding. Sequences with 36% identity 
or no identity to the hen lysozyme mono-
mer had no effect on fibril formation.15 
Thus the efficiency of seeding depends on 
the similarity between both the seed’s and 
monomer’s amino acid sequence.15
Similar primary sequences between 
amyloidogenic proteins may promote the 
likelihood of a cross-seeding event occur-
ring, but this does not always result in 
a reciprocal ability for both partners to 
cross-seed each other’s assembly. Islet 
amyloid polypeptide (IAPP), the amy-
loidogenic peptide involved in type II 
diabetes mellitus, is derived from the 89 
amino acid precursor protein pro-islet 
amyloid polypeptide. Aβ, the neurotoxic 
agent in Alzheimer disease (AD), is 
derived from the proteolytic processing of 
amyloid precursor protein which, depend-
ing on the splicing isoform, is composed 
of 365 to 770 amino acids. These pre-
cursor proteins are unrelated in sequence 
and have no obvious functional relation-
ship. Despite this, residues 15–37 of Aβ 
(residues involved in the amyloid core of 
Aβ fibrils16) share 39% sequence identity 
and 65% sequence similarity with residues 
10–33 of IAPP. The interaction between 
IAPP and Aβ40 was studied to deter-
mine whether cross-seeding could occur.17 
These in vitro studies showed that Aβ40 
fibrils, IAPP fibrils, and IAPP amor-
phous aggregates are all equally effective 
at seeding elongation with IAPP mono-
mer. Conversely, IAPP aggregates will not 
cross-seed polymerization of Aβ40, and 
IAPP fibrils are much less efficient at seed-
ing Aβ40 monomer compared with Aβ40 
fibrils, exhibiting only 2% of the seeding 
efficiency of Aβ fibrils on a weight basis.17 
Thus, there is a surprising lack of equiva-
lence in cross-seeding of Aβ40 and IAPP 
(Row 2, Table 1).
The importance of primary sequence 
in determining the ability of proteins to 
co-aggregate is more complex than both 
partners simply having amyloid-prone 
primary sequences. In one example, the 
ability of a variety of different amyloid 
fibrils to act as a seed for elongation with 
Aβ40 was compared with the efficiency of 
homologous seeding (Aβ40 seeds).17 The 
majority of fibril types, including fibrils 
formed from the yeast protein Ure2p 
and the human protein β
2
-microglobulin 
(β
2
m), were as inefficient at cross-seeding 
Aβ40 as non-amyloid protein aggregates 
such as collagen or denatured ovalbumin 
(Row 3 of Table 1). Thus simply being 
amyloidogenic does not necessarily result 
in an ability to seed elongation with other 
non-homologous amyloidogenic proteins; 
sequence similarity is required as well.
Sequence similarity is not the only 
important factor in determining the pro-
pensity for co-aggregation in amyloid 
formation as the precise positioning of 
compatible residues within the structure 
also plays a significant role. For exam-
ple, co-incubation of murine and human 
Aβ40 and Aβ42 peptides revealed that 
interspecies fibrils will form for both 
Aβ40 and Aβ42 alloforms (Row 4, 
Table 1)18 despite the three residue dif-
ference in the mouse and human amino 
acid sequences. This is because the residue 
differences between human and murine 
Aβ (Arg5Gly, Tyr10Phe, and His13Arg) 
are located toward the N-terminal region 
of the peptides, a region not thought to 
take part in the β-structure of Aβ fibrils.16 
Interestingly the mixed fibrils containing 
murine and human Aβ42 were more sta-
ble in solubilizing buffers than the homo-
polymeric human Aβ42 fibrils.18 Murine 
Aβ peptide contains a larger amount of 
β-turn structure and is more strongly sta-
bilized by hydrogen bonds than human 
Aβ.19 The increased number of hydrogen 
bonds may stabilize the mixed fibrils, 
resulting in a greater resistance to buffer 
solubilization compared with homopoly-
meric human fibrils. This study demon-
strates how mixing proteins with different 
primary sequences can result in the emer-
gence of new fibril polymorphs with dif-
ferent biophysical properties.
The ability of human Aβ and its 
murine homolog to co-polymerize is con-
sistent with the other studies outlined 
above, as reflected by the percentage of 
overall sequence similarity between the 
two peptides (~93% identity for Aβ40 
and Aβ42). Other studies show that the 
presence of a non-homologous amyloido-
genic protein can inhibit fibril formation 
because both the number and position of 
differences in the primary sequences are 
incompatible with fibril elongation and/
or nucleation, e.g., human and murine 
β
2
m (70% sequence similarity).20 In an 
elegant study in which heterotetramers 
of transythyretin (TTR) were formed by 
mixing its human and murine subunits 
(Row 5, Table 1) Kelly and coworkers dem-
onstrated that incorporation of murine 
TTR subunits protects the amyloidogenic 
human TTR from aggregating by stabi-
lizing the native state.21,22 Similar results 
were observed for the mutant Thr119Met 
of human TTR which protects wild-type 
TTR tetramers from dissociation both in 
vitro and in vivo (Row 6, Table 1).23 In 
both cases amyloid formation is inhibited 
via kinetic stabilization of the resulting 
heterotetramers relative to their homo-
tetrameric human counterparts. Thus, 
using variants of amyloidogenic sequences 
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Table 1. Interactions between amyloidogenic proteins
Protein 1 Protein 2
Type of cross-
interaction
Effect on interaction References
1 Hen lysozyme
I55T Hen lysozyme (99.2% sequence 
identity to hen lysozyme)
Turkey lysozyme (95% identity)
Human lysozyme (60% identity)
Human α-lactalbumin (36% identity)
Bovine insulin (no identity)
Cross-seeding Sequences must be > 60% identical to cross-seed efficiently 15
2 Aβ40 IAPP Cross-seeding
Aβ fibrils will cross-seed IAPP monomer, but IAPP fibrils 
are inefficient at cross-seeding Aβ40 monomer
17
3 Aβ40
IAPP
ΚIV light chain LEN-(1–30)
Polyglutamine Gln
30
Polyglutamine Gln
50
Ure2p
ΛtVI light chain JT05
β
2
-microglobulin
Collagen
Ovalbumin-RA
Cross-seeding
All the proteins listed showed less than 6% of 
the seeding efficiency of homologous seed-
ing (Aβ40 seeds with Aβ40 monomer)
17
4
Human Aβ40 
and Aβ42
Murine Aβ40 and Aβ42 Co-incubation
Interspecies fibril formation occurs and mixed fibrils are 
more stable than homopolymeric human Aβ fibrils
18
5 Human TTR Murine TTR Co-incubation
Murine TTR subunits stabilize the mixed tetra-
mer and inhibition of fibril formation occurs
22
6
Human wild-
type TTR
Human T119M TTR Co-incubation
T119M TTR subunits stabilize the mixed tetra-
mer and inhibition of fibril formation occurs
23
7 Human β
2
m Human ΔN6 Co-incubation
ΔN6 monomer causes β
2
m fibril formation and formation 
of heteropolymeric fibrils with distinct morphology result
20,30
8 Aβ40 Aβ40
ARC
Co-incubation Stabilization of protofibrils occurs 32
9 Tau α-synuclein Co-incubation
Both proteins induce fibrillation of each 
other into homopolymers
33,57
10 Aβ42 α-synuclein Co-incubation Aβ42 and α-synuclein form hybrid nanopore oligomers 36
11
Human vCJD 
prions and 
human classical 
CJD prions
Mouse PrP Cross-seeding
Human vCJD prions, but not classical CJD prions, induce 
formation of prions in mice with faithful strain replication
26,38
12
Hamster PrP 
R- and S-strain
Mouse PrP Cross-seeding
The fibrillar R-strain of hamster PrP acts as a catalyst and 
a template for mouse PrP fibril formation, whereas the 
fibrillar hamster PrP S-strain could only act as a catalyst
39
13 Rnq1 Ure2p and Sup35 Cross-seeding
The ability to cross-seed Ure2p and Sup35 by 
the prion form of Rnq1 is strain dependent
41
14 Sup35 Ure2p Cross-seeding Sup35 prion inhibits fibril formation of Ure2p 41
15 Aβ40 Aβ42 Co-incubation
Aβ42 monomer stimulates fibril formation of 
monomeric Aβ40, but Aβ40 monomer inhib-
its fibril formation of monomeric Aβ42
42
16 Aβ40 Aβ42 Cross-seeding
Aβ40 seeds both monomeric Aβ40 and monomeric 
Aβ42 equally well, but fibrillar Aβ42 is inefficient at 
seeding A40 monomer compared with fibrillar Aβ40
42
17 Aβ40 and Aβ42 PrPC Co-incubation
PrPC inhibits Aβ fibril formation and traps it in an oligo-
meric state. Amyloid-β oligomers bind with nanomolar 
affinity to PrPC and the interaction is required for toxicity
43,44
18 Insulin TTR Co-incubation
The kinetics of fibril formation of both protein 
partners must be evenly matched for cross-
seeding to occur, as with insulin and TTR
45
19 Aβ40 Cystatin C Co-incubation Cystatin C inhibits Aβ40 formation 49,50
20 Aβ40 TTR Cross-seeding Preincubation of Aβ40 with TTR reduced cytotoxicity 51
21 Aβ40 Neuroserpin Co-incubation Aβ40 acts as a catalyst of neuroserpin polymerization 58
www.landesbioscience.com Prion 363
allows amyloid formation to be controlled 
and/or inhibited by introducing a non-
homologous primary sequence into a fibril 
formation reaction.
Condition 2: Co-Aggregation 
Occurs by One Partner Protein 
Affecting the Rate of Fibril 
Formation of Another
Amyloidoses can occur when suscep-
tible proteins are exposed to conditions 
that promote global unfolding of the native 
state24 or enhance the population of amy-
loidogenic intermediates.25 Statistically, 
mixed fibril formation is less likely than the 
generation of fibrils from a single sequence, 
as the production of heterofibrils requires 
a change in conformation of two proteins 
instead of one. However, this assumes that 
both partners must undergo a change to 
an amyloid conformer independently. By 
contrast with this observation, monomer-
monomer interactions can promote protein 
unfolding, and/or formation of an amy-
loidogenic fold.20,26 Thus if one protein 
partner acts to enhance the amyloid poten-
tial of another, the probability of forming 
heteropolymeric assemblies is increased.
An excellent example of one protein 
enhancing the amyloid propensity of 
another has been shown for β
2
m and its 
N-terminally truncated variant ΔN6.20 
β
2
m forms amyloid fibrils in vivo result-
ing in the disease dialysis-related amyloi-
dosis (DRA).27 However, in the absence 
of other co-factors or co-solvents human 
β
2
m will not form fibrils in vitro at neu-
tral pH within an experimentally trac-
table timescale,28,29 while ΔN6 is highly 
aggregation prone.20,30 Surprisingly, when 
monomeric human β
2
m is mixed with 
monomeric ΔN6 fibril formation from 
both proteins occurs, resulting in het-
eropolymeric fibrils, even at neutral pH 
(Row 7, Table 1).20,30 Interestingly ΔN6 
was shown to stimulate fibril formation 
of human β
2
m at sub-stoichiometric lev-
els, with fibril formation occurring at a 
1:99 ΔN6:β
2
m molar ratio.20 An atom-
istic description of how ΔN6 converts 
β
2
m into an amyloidogenic form has been 
provided using NMR.20 These studies 
showed that collision with ΔN6 results 
in increased conformational dynamics of 
human β
2
m, allowing β
2
m to undergo 
further structural rearrangements, criti-
cally via cis-trans isomerization of Pro32, 
that subsequently allows access to the 
amyloid state.
By enhancing the amyloid potential 
of β
2
m, both β
2
m and ΔN6 are incorpo-
rated into heteropolymeric fibrils when 
incubated at a 1:1 ratio.30 As discussed 
in the introduction, aggregation of a sin-
gle polypeptide sequence can result in a 
range of fibril structures dependent on the 
experimental conditions employed, such 
as pH, temperature, ionic strength and 
agitation.31 In the case of mixed fibrils, 
for example those formed from β
2
m and 
ΔN6 where both proteins are incorpo-
rated into the fibril structure, the possi-
bilities for polymorphism are vast. Perhaps 
unsurprisingly then, the heteropolymeric 
fibrils formed from β
2
m and ΔN6 do not 
resemble those formed from β
2
m alone at 
acidic pH or from ΔN6 alone at neutral 
pH. Instead biophysical experiments have 
shown that the heteropolymeric fibrils 
of β
2
m/ΔN6 form a unique polymorph 
that is thermodynamically less stable 
than both β
2
m and ΔN6 homopolymeric 
fibrils.30 These findings show that the 
heteropolymorphic fibrils do not possess 
“average” structural or thermodynamic 
characteristics resulting from mixing of 
Table 1. Interactions between amyloidogenic proteins
Protein 1 Protein 2
Type of cross-
interaction
Effect on interaction References
22 Aβ42 Neuroserpin Co-incubation
Neuroserpin accelerates Aβ42 aggrega-
tion to form non-toxic oligomers
59
23 Murine β
2
m ΔN6 Co-incubation Inhibition of fibril formation 20
24 Gliadin Amylase/myoglobin Co-incubation
Varied fiber morphologies form when the 
proteins are incubated together
60
25
Aβ6–40
Aβ26–42
Aβ34–42
Aβ26–43
Aβ26–39
Aβ26–40
Cross-seeding
All the proteins in the Protein 1 column accelerate fibril 
formation of monomeric Aβ26–39 and Aβ26–40
61
26 Aβ42 Pyroglutamate Aβ42 Cross-seeding
Cross-seeding accelerated fibril forma-
tion and resulted in increased toxicity
62
27 Aβ40 α-synuclein Cross-seeding
Fibrillar α-synuclein is more effective than fibrillar Aβ40 at 
cross-seeding Aβ40, oligomeric α-synuclein is less effective 
than oligomeric Aβ40 at cross-seeing Aβ40. Aβ40 fibrils 
and oligomers are a poor seed of monomeric α-synuclein
63
28 Aβ42 α-synuclein Cross-seeding
Fibrillar and oligomeric α-synuclein are less effective than 
oligomeric and fibrillar Aβ42 at seeding monomeric Aβ42. 
Aβ42 fibrils and oligomers are both less effective than 
α-synuclein fibrils and oligomers at seeding α-synuclein
63
29 Aβ40 BRICHOS Cross-seeding Extension of the Aβ40 lag phase in the presence of BRICHOS 64
30 Aβ40 IAPP mimic ([N-Me]G24, [N-Me]I26)-IAPP Cross-seeding An IAPP mimic inhibits Aβ40 fibril formation 65
Interactions between two amyloidogenic proteins of different primary sequences are shown. The types of interactions are either cross-seeding, where one 
protein is oligomeric or fibrillar and the other protein is monomeric, or co-incubation, where the two proteins are mixed as monomers. The effect of the 
interaction on the propensity for fibril formation is also described.
(continued)
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the two precursors. Instead, through the 
enhancement of the amyloidogenic poten-
tial of one protein by another, a new area 
of the protein (mis)folding landscape is 
sampled, and a new polymorph is created.
The ability to endow an amyloid-
prone form on a less amyloidogenic pro-
tein can also result in altered stabilities 
of on-pathway intermediates. The Arctic 
mutation (E22G) of Aβ40 results in a 
highly amyloidogenic protein (Aβ40
ARC
) 
that forms both protofibrils and fibrils 
under conditions in which Aβ40 remains 
monomeric.32 Interestingly in the absence 
of Aβ40, Aβ40
ARC
 protofibrils will con-
vert to fibrils, but in the presence of 
Aβ40 at a 1:1 molar ratio, the two pro-
teins form mixed protofibrils that are 
incapable of further assembly. The mixed 
protofibrils are more stable than the pro-
tofibrils formed by Aβ40
ARC
 alone and 
hence these species accumulate (Row 8, 
Table 1). Lashuel et al. postulate that 
these mixed protofibrils may be responsi-
ble for the enhancement of neurotoxicity 
and accelerated disease progression that is 
seen in patients carrying this mutation.32 
Co-aggregation of two different peptides, 
therefore, can alter the kinetics of fibril 
formation, and thereby alter the mor-
phology and stability of intermediates, 
resulting in a prolonged lifetime of toxic 
species.
A highly specific enhancement of 
one protein’s amyloidogenic potential 
by another is demonstrated by the co-
incubation of tau with a familial mutant 
of α-synuclein (Ala53Thr). This amino 
acid substitution results in increased 
α-synuclein and tau inclusions, suggest-
ing that it not only increases the pro-
pensity for α-synuclein to form fibrils, 
but also promotes the formation of tau 
inclusions.33 Further in vitro studies have 
shown that co-incubation of tau and 
α-synuclein induces polymerization of 
both proteins and this effect was observed 
for all six tau isoforms (Row 9, Table 1).33 
Immunogold labeling revealed that the 
individual fibrils are mostly homopoly-
mers, but some fibrils were labeled for 
both α-synuclein and tau but in spatially 
separate domains, suggesting that end-
to-end annealing of the homopolymers 
occurs.33 Furthermore, at low concentra-
tions of α-synuclein, the presence of tau 
was required for α-synuclein fibrils to 
form. Similarly, tau requires α-synuclein 
pre-aggregation to induce the requi-
site conformational change to allow tau 
inclusion formation. Interestingly, this 
effect was specific to α-synuclein; other 
amyloidogenic proteins such as Aβ40 are 
unable to initiate tau polymerization.33
Enhancing a protein’s amyloid poten-
tial not only results in increased forma-
tion of fibrils, but new species in the 
amyloidogenic pathway can also form 
by mixing protein monomers. Aβ has 
been shown to promote the aggregation 
and toxicity of α-synuclein in a dose- 
and time-dependent manner.34 The two 
proteins may also interact in vivo as evi-
denced by an overlap in the pathology of 
AD and Parkinson Disease in Lewy Body 
Disease (LBD), where the initial signs are 
dementia followed by parkinsonism.35 In 
samples of human brains from sufferers of 
LBD Aβ and α-synuclein were shown to 
co-immunoprecipitate, but no interaction 
between the two proteins was observed 
in non-demented controls. In vitro stud-
ies have shown that solubilized Aβ42 
induces formation of α-synuclein tetra-
mers and higher-order oligomers (Row 10, 
Table 1).36 Electron microscopy images of 
the mixture after 6 h show well-defined 
hybrid ring oligomeric structures 9–15 nm 
in diameter, which may form functional 
cation nanopores.36 Mixing two amy-
loidogenic proteins, therefore, can change 
the stability and characteristics of species 
that form during amyloid assembly, in this 
case resulting in the formation of a hybrid 
nanopore that could be involved in disease 
progression.
Condition 3: Structure 
and Post-Translational 
Modifications Affect the 
Efficiency of Cross-Seeding
One of the most striking examples of 
post-translational modification altering 
protein co-aggregation is in prion diseases. 
In these disorders the efficiency of cross-
species infectivity is partly determined by 
primary sequence, but also relies on com-
patible structures and post-translational 
modifications (typically glycosylation).37 
Furthermore, to efficiently cross-seed, 
both the seed and the monomer must 
be able to adopt the same amyloidogenic 
conformation.
The importance of structure in prion 
propagation was demonstrated with the 
bovine spongiform encephalopathy (BSE) 
outbreak in the UK in the mid-1980s 
which resulted in the infection of more 
than 2 million UK cattle.37 This was fol-
lowed by an outbreak of a novel human 
prion disease, variant Creutzfeldt-Jakob 
disease (vCJD) in the mid-1990s. CJD is 
not a new disease: “classical” CJD prions, 
formed from spontaneous misfolding of 
the prion protein (PrP), occur at a rate of 
approximately one case per 1 million pop-
ulation per year.37 However, despite shar-
ing identical primary sequences, classical 
CJD prions and vCJD prions behave very 
differently in their ability to convert PrPC 
(the non-infectious form of PrP) to PrPSc 
(the prion form) in a new species. This 
was shown when human classical CJD 
prions were used to infect wild-type mice, 
wherein no transmission was observed. 
However, when human vCJD prions were 
used instead, transmission was much more 
successful and the resultant mouse PrP 
showed faithful strain replication of the 
vCJD strain.38 Fascinatingly, this shows 
that two proteins with identical amino 
acid sequences can experience different 
species barriers, confirming that prion 
propagation is conformation dependent 
(Row 11, Table 1).
Although the vCJD and classical CJD 
strains of PrP have identical primary 
sequences, they differ in their glycosyl-
ation patterns. Classical CJD strains are 
modified predominantly with low molec-
ular mass glycosylation, whereas the vCJD 
strain has high molecular mass glycosyl-
ation.26 Furthermore, the ratio of the three 
PrP glycoforms (unglycosylated, monogly-
cosylated, and diglycosylated) is faithfully 
maintained on passage in transgenic mice 
expressing human PrP.26 Similarly, trans-
mission of human prions and bovine pri-
ons to wild-type mice results in murine 
PrP with glycoform ratios that correspond 
to the initial inocula.26 Interestingly, PrP 
glycosylation occurs before conversion to 
PrP, thus the different glycoforms may be 
determined by initial PrP conformation. 
Different cell types may also glycosyl-
ate proteins differently, thus particular 
PrP glycoform strains may replicate most 
www.landesbioscience.com Prion 365
favorably in cell types with a similar PrP 
glycoform expressed on the cell surface.37 
Glycosylation similarities (or differences) 
between PrP and the infectious prion may 
help to explain the different incubation 
periods seen in individuals with prion 
disease.26 Thus post-translational modifi-
cations can be crucial in determining the 
propensity of a protein to cross-seed, as 
well as affecting the location and times-
cale of disease developing.
In a recent study the importance of 
strain for cross-species infectivity was 
demonstrated using two morphologies 
of hamster prion protein, R and S.39 The 
two strains were formed using the same 
stock of recombinant PrP under identical 
solvent conditions, but with different agi-
tation modes; the S-strain was produced 
under shaking, the R-strain was produced 
with rotation. The R- and S-fibrils display 
substantial differences in their cross-β 
cores, epitope exposure and morphology.40 
Despite sharing the same amino acid 
sequence, the difference in morphology 
between the R- and S-fibrils has a pro-
found effect on their ability to reproduce 
their strain faithfully in a different species 
(mouse). The hamster R-fibrils success-
fully recruit mouse-PrP into fibrils and 
maintain their morphology, thus acting 
both as a so-called “catalyst” and a tem-
plate for fibril formation of mouse PrP. By 
contrast, the hamster S-fibril form also 
acts as a catalyst for structural conversion 
of mouse-PrP, but does not act as a tem-
plate, i.e., the strain morphology was not 
propagated (Row 12, Table 1).39 In the 
latter case, fibril elongation occurred but 
involved mouse-PrP switching to a new 
conformational state that resembled the 
R-fibril form. This demonstrates that pri-
mary sequence (condition 1) is not wholly 
responsible for the ability to act as an 
enhancer of amyloidogenicity in another 
protein (condition 2). Instead structure 
also affects the ability to transmit disease 
across a species barrier.
Yeast prion proteins have also provided 
a powerful model for developing under-
standing of both sequence and strain 
effects in prion propagation. When the 
yeast protein Rnq1 is aggregated into its 
prion form, it can promote prion forma-
tion of two other proteins, Sup35 and 
Ure2p.41 Interestingly the efficiency with 
which the prion form of Rnq1 can cross-
seed the latter two proteins is dependent 
on its strain. One Rnq1 prion strain will 
seed Ure2p inefficiently, but will seed 
Sup35 efficiently. However an alternative 
Rnq1 prion strain behaves in the oppo-
site manner, inefficiently seeding Sup35, 
but efficiently seeding Ure2p. Both Rnq1 
prion strains can propagate their morphol-
ogy by homologous seeding, yet their abil-
ity to cross-seed other proteins is entirely 
dependent on their structure, rather than 
their (identical) amino acid sequence 
(Row 13, Table 1).41 Further revelations 
from yeast models show that not all pri-
ons can cross-seed, and some can even 
inhibit homologous seeding.41 For exam-
ple, the prion form of Sup35 will inhibit 
Ure2p prion seeds from seeding non-prion 
Ure2p, through “poisoning” of the Ure2p 
prion seeds (Row 14, Table 1).41
The importance of structure in amy-
loid propagation is not limited to prion 
interactions. Despite Aβ40 and Aβ42 dif-
fering by only two residues, the two pep-
tides have different effects on each other’s 
aggregation propensity. In co-polymeriza-
tion experiments Aβ42 monomers stimu-
late Aβ40 monomers to aggregate, whereas 
Aβ40 monomers shows a concentration-
dependent inhibitory effect on Aβ42 fibril 
formation (Row 15, Table 1).42 However, 
the same effect is not seen in cross-seeding 
experiments (Row 16, Table 1),42 where 
one partner is in fibrillar form and one 
partner is monomeric. In this case Aβ42 
fibrils are less efficient than fibrillar Aβ40 
at inducing fibril formation of monomeric 
Aβ40. Why does Aβ42 efficiently stimu-
late Aβ40 amyloidogenesis only when it is 
monomeric, and not when in the fibrillar 
form? This phenomenon is explained by 
the importance of structure, as well as pri-
mary sequence for promoting amyloid for-
mation. Accordingly, it is Aβ42 oligomers, 
rather than fibrils, that are the optimal 
template for incorporating Aβ40 mono-
mers, and these are mainly populated 
during incubation of soluble Aβ40 and 
Aβ42 (co-polymerization), rather than 
when Aβ42 is added as fibrils (cross-seed-
ing). Thus, although primary sequence is 
important in allowing Aβ42 and Aβ40 
co-aggregation to occur (condition 1), and 
Aβ42 is an enhancer of Aβ40 amyloido-
genesis (condition 2), the inclusion of the 
structure of Aβ42 aggregates must also be 
considered in assessing the likelihood of 
co-aggregation occurring.
A final example of a structure-
dependent interaction of two amyloido-
genic proteins is between PrP and Aβ. 
Interactions between Aβ42 oligomers 
and PrP leads to the inhibition of long-
term potentiation in hippocampal slices 
from mice.43 Interestingly, experiments 
using NMR have shown that PrP does 
not interact with disordered monomeric 
Aβ40, but Aβ40 must first change its 
conformation, possibly forming a mis-
folded monomer or dimer.44 These stud-
ies not only highlight the importance of 
structure in determining co-aggregation, 
but also show that interactions are not 
limited to the monomer-monomer or 
monomer-fibril stages in fibril formation. 
Instead, recognition between two amy-
loidogenic proteins can be specific for a 
key intermediary structure in the amyloid 
formation pathway.
Conclusions
This review broadly categorizes inter-
actions between two amyloidogenic pro-
teins into “conditions” that prescribe 
the likelihood of a co-polymerization or 
cross-seeding event occurring. The first 
condition is that both partners must have 
a similar amino acid sequence. Although 
the importance of the protein backbone 
in fibril stability means most proteins may 
have the propensity to form fibrils under 
defined conditions,14 side-chain packing 
also plays a vital role.5 Interestingly the 
ability to cross-seed is not necessarily recip-
rocal, even between closely related amyloid 
proteins.17 The second condition is that at 
least one of the partners must enhance 
the amyloidogenic potential of the other, 
such as the effect of ΔN6 on β
2
m20,30 or 
α-synuclein on tau.33 Finally, the third 
condition is that structure and/or post-
translational modifications can affect the 
efficiency of cross-seeding, for example in 
prion propagation across different species. 
The three conditions are not mutually 
exclusive: primary sequence can influence 
fibril/oligomer structure, and a similarity 
in sequences between amyloidogenic pro-
teins with their less amyloidogenic part-
ners is important in defining the ability of 
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proteins to co-polymerize. The network of 
hydrogen bonds within a fibril is known 
to be vital for monomer addition, and this 
would be influenced by both side-chain 
and fold. The conditions outlined here 
are also not comprehensive: another prop-
erty that can regulate the propensity for 
co-polymerization is similar aggregation 
kinetics of the co-incubated monomers 
(Row 18, Table 1).45 Additionally the ratio 
of the two components may also be vital: 
under normal physiological conditions the 
Aβ42:Aβ40 ratio in the brain is ~1:9.46 
However, in familial AD patients a ratio 
of 3:7 Aβ42:Aβ40 is observed, suggesting 
that a change in the proportion of the two 
alloforms may be significant in the devel-
opment of AD.47
Examples of co-polymerization 
between unrelated sequences in vivo are 
relatively rare. The BSE crisis followed 
by the outbreak of vCJD has shown that 
cross-species prion transmission can 
occur.37 An increased risk of AD has been 
shown for type II diabetes sufferers, sug-
gesting a possible link between Aβ and 
IAPP aggregation.48 In fact, Aβ seems 
to be promiscuous, with in vivo interac-
tions reported between Aβ and cystatin 
c (Row 19, Table 1)49,50, TTR (Row 20, 
Table 1)51, and neuroserpins (Rows 21 
and 22, Table 1).52 The lack of more 
examples in vivo suggests that perhaps all 
three conditions described here need to 
be met, in a timely and spatially defined 
manner, for co-polymerization and/or 
cross-seeding to occur. Additionally the 
rapid increase in examples reported in the 
literature of co-polymerization and cross-
seeding between different amyloidogenic 
proteins in vitro confirms the possibility 
for co-polymerization, giving weight to a 
possible in vivo relevance to at least some 
of these interactions.
Interactions between unrelated, or 
sequence distinct amyloidogenic proteins 
are fascinating and important because of 
the possibilities for polymorphism that 
arise from co-aggregation. In the intro-
duction of this review the eight different 
classes of steric zippers that comprise the 
amyloid core were discussed5 and detailed 
studies of polymorphism in homopoly-
meric fibrils have been performed.1,4,53 
Additionally polymorphism can occur 
at the earliest stages of aggregation, with 
subsets of oligomers showing structural 
polymorphism that also affects the abil-
ity of the species to be toxic (reviewed in 
ref. 54). Polymorphism has been induced 
in proteins with the same sequence 
through alteration of solution conditions 
such as pH, agitation, temperature and/
or ionic strength.31,55 Fibril length can also 
be controlled via fragmentation, allow-
ing the physical dimensions and surface 
interactions of fibrils to be studied.56 
However, more parameters are also open 
to manipulation in systems that co-aggre-
gate, such as the ratio of the protein species 
involved and the identity of the species that 
are mixed (monomers, oligomers or fibrils). 
By adjusting these different factors, in addi-
tion to altering experimental constraints, 
the potential repertoire of species that can 
form, both at the level of oligomers and 
fibrils is vast (see the schematic in Fig. 1B). 
Furthermore, as all proteins are potentially 
able to form amyloid,14 and some amy-
loidogenic proteins can cross-seed unre-
lated polypeptide sequences, the risk of 
co-polymerization could potentially extend 
to the entire proteome. Unravelling the dif-
ferent structural possibilities for oligomer 
and fibril architectures and defining their 
physical and biological characteristics will 
be challenging. However these multi-com-
ponent assemblies will need to be defined 
for developing our understanding of the 
causative agents of amyloid disease, as well 
as to harness the future potentials of amy-
loid fibrils as designer nanomaterials. 
Recent work has shown that a spe-
cific and transient protofibrillar species of 
Abeta42, with a novel triple helical struc-
ture, is the most potent aggregate involved 
in the interaction between PrP and Abeta.66 
This works supports the importance of 
structure for influencing amyloid interac-
tions between different proteins.
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